Institute of Tropical Medicine Antwerp
Foundation of Public Utility

Tuberculosis drug resistance in Bamako, Mali, from 2006 to 2014

DSpace/Manakin Repository

Show simple item record

dc.contributor.author Diarra, B. en_US
dc.contributor.author Goita, D. en_US
dc.contributor.author Tounkara, S. en_US
dc.contributor.author Sanogo, M. en_US
dc.contributor.author Baya, B. en_US
dc.contributor.author Togo, A. C. en_US
dc.contributor.author Maiga, M. en_US
dc.contributor.author Sarro, Y. S. en_US
dc.contributor.author Kone, A. en_US
dc.contributor.author Kone, B. en_US
dc.contributor.author M'Baye, O. en_US
dc.contributor.author Coulibaly, N. en_US
dc.contributor.author Kassambara, H. en_US
dc.contributor.author Cisse, A. en_US
dc.contributor.author Belson, M. en_US
dc.contributor.author Polis, M. A. en_US
dc.contributor.author Otu, J. en_US
dc.contributor.author Gehre, F. en_US
dc.contributor.author Antonio, M. en_US
dc.contributor.author Dao, S. en_US
dc.contributor.author Siddiqui, S. en_US
dc.contributor.author Murphy, R. L. en_US
dc.contributor.author de Jong, B. C. en_US
dc.contributor.author Diallo, S. en_US
dc.date.accessioned 2017-12-18T12:55:58Z
dc.date.available 2017-12-18T12:55:58Z
dc.date.issued 2016 en_US
dc.identifier.issn 1471-2334 en_US
dc.identifier.doi http://dx.doi.org/10.1186/s12879-016-2060-7 en_US
dc.identifier.other http://lib.itg.be/pdf/itg/2016/2016bidi0714.pdf en_US
dc.identifier.other 8 pp. en_US
dc.identifier.other 13 en_US
dc.identifier.other ITG-B18A; ITG-B23A; DBM; U-MYCOB; JIF; DOI; PDF; PMC; OAJ; E-only; Abstract; DSPACE64 en_US
dc.identifier.uri http://hdl.handle.net/10390/9762
dc.description.abstract BACKGROUND: Although Drug resistance tuberculosis is not a new phenomenon, Mali remains one of the "blank" countries without systematic data. METHODS: Between 2006 and 2014, we enrolled pulmonary TB patients from local TB diagnostics centers and a university referral hospital in several observational cohort studies. These consecutive patients had first line drug susceptibility testing (DST) performed on their isolates. A subset of MDR was subsequently tested for second line drug resistance. RESULTS: A total of 1186 mycobacterial cultures were performed on samples from 522 patients, including 1105 sputa and 81 blood samples, yielding one or more Mycobacterium tuberculosis complex (Mtbc) positive cultures for 343 patients. Phenotypic DST was performed on 337 (98.3%) unique Mtbc isolates, of which 127 (37.7%) were resistant to at least one drug, including 75 (22.3%) with multidrug resistance (MDR). The overall prevalence of MDR-TB was 3.4% among new patients and 66.3% among retreatment patients. Second line DST was available for 38 (50.7%) of MDR patients and seven (18.4%) had resistance to either fluoroquinolones or second-line injectable drugs. CONCLUSION: The drug resistance levels, including MDR, found in this study are relatively high, likely related to the selected referral population. While worrisome, the numbers remained stable over the study period. These findings prompt a nationwide drug resistance survey, as well as continuous surveillance of all retreatment patients, which will provide more accurate results on countrywide drug resistance rates and ensure that MDR patients access appropriate second line treatment. en_US
dc.language English en_US
dc.relation.uri http://www.ncbi.nlm.nih.gov/pubmed/27894266 en_US
dc.subject Tuberculosis-multidrug-resistant en_US
dc.subject Bacterial diseases en_US
dc.subject Drug resistance en_US
dc.subject Mali en_US
dc.subject Africa-West en_US
dc.title Tuberculosis drug resistance in Bamako, Mali, from 2006 to 2014 en_US
dc.type Article-E en_US
dc.citation.issue 1 en_US
dc.citation.jtitle BMC Infectious Diseases en_US
dc.citation.volume 16 en_US
dc.citation.pages 714 en_US
dc.citation.abbreviation BMC Infect Dis en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record